Double antibody-conjugate techniques were employed to assess whether CD30 expression was representative of tumor, or of tumor-infiltrating inflammatory cells such as cytotoxic T-lymphocytes or macrophages.27 While these techniques are not widely available, these results raise interesting questions about the contribution of the tumor microenvironment to lymphomagenesis, the specificity of CD30 as a treatment target, and how to best assess patient suitability for anti-CD30 therapies. Here, TNFRSF8 is linked to neoplasm.